معرفی
Dr. Serge Korjian is a prominent figure in clinical cardiology, currently serving as the Senior Medical Director of Clinical Trials and Director of the Angiographic Core Lab at the Baim Institute for Clinical Research. He is also an Instructor of Medicine at Harvard Medical School and an Attending Physician in Interventional Cardiology at Massachusetts General Hospital. His affiliations span leading institutions in cardiovascular research, including collaborations with Dr. C. Michael Gibson on international trials like APEX, AEGIS-I/II, PIONEER AF-PCI, and HEARTLINE.
Dr. Korjian's research focuses on antiplatelet and anticoagulant therapies, lipid-modifying interventions, and novel devices for acute coronary syndromes. His expertise includes clinical trial design, protocol development, safety monitoring, and cardiovascular data analysis. Key contributions address residual risk in post-MI patients, cost-effectiveness of diagnostics, and bleeding prevention in AF-PCI cohorts.
His recent publications highlight innovations in apolipoprotein A-I infusions, angiographic imaging, and risk prediction tools. Trends in his work emphasize patient-centric outcomes, digital trial recruitment, and the intersection of biomarkers (e.g., D-dimer, cholesterol efflux capacity) with clinical endpoints. While no formal scientific awards are disclosed in the text, his leadership in core labs and endpoint adjudication underscores his academic impact.
Dr. Korjian's career bridges academic leadership with hands-on involvement in global clinical trials. He previously trained at the PERFUSE study group and Beth Israel Deaconess Medical Center, where he honed skills in interventional cardiology and statistical analysis. His current roles position him at the forefront of translational cardiovascular research and trial methodology.
